- Home
- BMY
as 12-20-2024 4:00pm EST
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
| Founded: | 1887 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 120.4B | IPO Year: | N/A |
| Target Price: | $55.93 | AVG Volume (30 days): | 9.9M |
| Analyst Decision: | Hold | Number of Analysts: | 15 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | -3.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $39.35 - $61.08 | Next Earning Date: | 02-06-2025 |
| Revenue: | $47,435,000,000 | Revenue Growth: | 5.56% |
| Revenue Growth (this year): | 7.22% | Revenue Growth (next year): | 0.16% |
Latest Bristol-Myers Squibb Company News
BMY Breaking Stock News: Dive into BMY Ticker-Specific Updates for Smart Investing
Insider Monkey
18 hours ago
Jim Cramer on Bristol-Myers Squibb Company (BMY): ‘This Stock Has Been Hot Since The Summer’
Zacks
a day ago
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
Investor's Business Daily
a day ago
Bristol Myers Squibb Stock Earns 83 RS Rating
Insider Monkey
a day ago
Jim Cramer on Bristol-Myers Squibb (BMY): Why Schizophrenia Drug Cobenfy Could Change the Game
MT Newswires
a day ago
Bristol-Myers Squibb Signs Exclusive License Deal With BioArctic for Antibody Program
Motley Fool
a day ago
3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income
Business Wire
a day ago
Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025
Motley Fool
a day ago
Got $250? 2 Healthcare Stocks to Buy and Hold Forever
Compare BMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMY Bristol-Myers Squibb Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.